Franklin Templeton
Franklin Pharma Fund - Dividend
Category
Growth
Plan type
Growth
Structure
Open-ended
AMFI Scheme Code
102271
ISIN (Growth)
—
ISIN (Dividend)
—
Returns matrix
Fund return alongside the category average and peer rank for every standard window. Returns under one year are absolute; one year and longer are compound annualised (CAGR).
| Window | Fund | Category avg | +/− vs avg | Rank | Quartile |
|---|---|---|---|---|---|
| 1D | — | — | — | — | — |
| 1W | -100.00% | -3.61% | -96.39 | 298 / 303 | Q4 |
| 2W | -100.00% | -4.52% | -95.48 | 298 / 303 | Q4 |
| 1M | -100.00% | -5.64% | -94.36 | 297 / 302 | Q4 |
| 3M | -100.00% | -4.27% | -95.73 | 297 / 302 | Q4 |
| 6M | -100.00% | +1.48% | -101.48 | 302 / 307 | Q4 |
| YTD | -100.00% | -0.18% | -99.82 | 304 / 309 | Q4 |
| 1Y | -100.00% | +7.10% | -107.10 | 302 / 307 | Q4 |
| 2Y | -100.00% | +2.20% | -102.20 | 296 / 303 | Q4 |
| 3Y | -100.00% | +0.76% | -100.76 | 257 / 264 | Q4 |
| 4Y | -100.00% | +0.58% | -100.58 | 228 / 235 | Q4 |
| 5Y | -100.00% | +0.02% | -100.02 | 201 / 208 | Q4 |
| 7Y | — | — | — | — | — |
| 10Y | — | — | — | — | — |
| Inception | -100.00% | +0.51% | -100.51 | 302 / 310 | Q4 |
Quartile legend: Q1 top 25% Q2 25-50% Q3 50-75% Q4 bottom 25%
Calendar-year returns
Full-year performance vs category average. Current year is partial (year-to-date).
| Year | Fund | Category avg | +/− vs avg | Rank |
|---|---|---|---|---|
| 2011 YTD | -100.00% | -23.68% | -76.32 | 240 / 241 |
| 2010 | +37.03% | +11.69% | +25.35 | 1 / 256 |
| 2009 | +111.20% | +65.86% | +45.34 | 9 / 238 |
| 2008 | -27.40% | -52.86% | +25.46 | 16 / 198 |
| 2007 | -9.81% | +42.91% | -52.73 | 132 / 137 |
| 2006 | — | — | — | — |
Rolling returns
Removes start-date bias by averaging CAGR over every overlapping N-year window in the fund's history. Higher average plus tight min/max plus high "% positive" = consistent.
1-Year rolling
+21.95%
54 windows
min -27.2% · max 155.8%
56% positive
Limited basis — fund is young, so this average may be skewed by which 1Y windows happen to be available.
3-Year rolling
+16.73%
29 windows
min -15.2% · max 33.8%
83% positive
Limited basis — fund is young, so this average may be skewed by which 3Y windows happen to be available.
5-Year rolling
+12.51%
5 windows
min 9.3% · max 16.1%
100% positive
Limited basis — fund is young, so this average may be skewed by which 5Y windows happen to be available.
7-Year rolling
—
Insufficient history
Recent NAVs
| Date | NAV |
|---|---|
| 12 Sep 2011 | ₹0.0000 |
| 9 Sep 2011 | ₹32.6086 |
| 8 Sep 2011 | ₹32.7389 |
| 7 Sep 2011 | ₹32.7092 |
| 6 Sep 2011 | ₹32.6387 |
| 5 Sep 2011 | ₹32.7002 |
| 2 Sep 2011 | ₹32.8137 |
| 30 Aug 2011 | ₹32.6959 |
| 29 Aug 2011 | ₹32.5207 |
| 26 Aug 2011 | ₹32.2564 |
Advertisement
Frequently asked questions
These answers are generated from this fund's live metrics — NAV, returns, peer rank, drawdown, SIP backtest. Numbers refresh nightly after AMFI's NAV feed lands.
Franklin Pharma Fund - Dividend is a Growth from Franklin Templeton (Unknown plan, Growth option). Latest NAV isn't currently available in our feed — the AMC publishes it once per business day after market close.
Franklin Pharma Fund - Dividend has NAV history starting from 03 Apr 2006, a track record of about 20 years 2 months. Long-tenured funds like this have weathered multiple market cycles — the 2008 crash, 2013 taper tantrum, 2020 COVID drawdown — which makes their returns more credible than a 3-year track record alone.
Franklin Pharma Fund - Dividend is managed by Franklin Templeton. It's classified by AMFI under the 'Growth' SEBI category, which determines its peer set and tax treatment.
Over the trailing 1-year window, Franklin Pharma Fund - Dividend has delivered a absolute return of -100.00% — -107.1 pp behind the Growth category average of 7.10%. The fund ranks #302 of 307 in its category — the bottom (Q4) quartile.
Over the trailing 3-year window, Franklin Pharma Fund - Dividend has delivered a CAGR of -100.00% — -100.76 pp behind the Growth category average of 0.76%. The fund ranks #257 of 264 in its category — the bottom (Q4) quartile.
Over the trailing 5-year window, Franklin Pharma Fund - Dividend has delivered a CAGR of -100.00% — -100.02 pp behind the Growth category average of 0.02%. The fund ranks #201 of 208 in its category — the bottom (Q4) quartile.
₹1 lakh invested in Franklin Pharma Fund - Dividend exactly 5 years ago would be worth approximately ₹0 today — a multiplier of 0.00×, based on the 5-year CAGR of -100.00%. The category average over the same window would have grown ₹1 lakh to ₹100,100.
We don't have enough NAV history yet to simulate a SIP on Franklin Pharma Fund - Dividend. The fund typically needs 12+ months for a 1-year SIP backtest.
Franklin Pharma Fund - Dividend doesn't have enough SIP-backtest history yet. Check the 1-year SIP simulation above as soon as it has 12+ months of NAVs.
On a 5-year basis, Franklin Pharma Fund - Dividend ranks #201 out of 208 funds in the Growth category — that places it in the bottom quartile (Q4) — material underperformance. The category average return over the same window is 0.02%; this fund delivered -100.00%.
Franklin Pharma Fund - Dividend doesn't have a computed drawdown figure yet.
Across all 5-year rolling windows, Franklin Pharma Fund - Dividend averaged 12.51% (best 16.07%, worst 9.26%). 100% of rolling windows ended positive.
In calendar year 2010, Franklin Pharma Fund - Dividend returned 37.03% — beating the Growth category average of 11.69% by 25.35 pp. It ranked #1 of 256 in its category that year.
Franklin Pharma Fund - Dividend doesn't fit cleanly into the standard Equity/Debt buckets in our taxonomy. Tax treatment depends on actual asset allocation as disclosed by the AMC — check the factsheet or AMFI's classification table.
We don't give personal investment advice. Franklin Pharma Fund - Dividend is suitable for an investor whose:
- understands what asset class this scheme actually invests in (check the factsheet)
- matches that asset class's volatility profile to their goal horizon
Educational content only — not investment advice. Tax rules summarised above reflect Budget 2024; consult a qualified adviser before transacting.
More from Franklin Templeton
- Franklin Asian Equity Fund - Dividend Plan
- Franklin Asian Equity Fund - Growth Plan
- Franklin India Flexi Cap Fund-Dividend Plan
- Franklin India Flexi Cap Fund-Growth Plan
- Franklin India High Growth Companies Fund - Dividend Plan
- Franklin India High Growth Companies Fund - Growth Plan
- Franklin India Index Fund- Nifty Plan - Dividend Plan
- Franklin India Index Fund- Nifty Plan - Growth Plan